Uncategorized Archives - Page 15 of 221

FridayMay 19, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pivotal Milestones Concerning DehydraTECH(TM) Technology, Including IND Application Plans

Lexaria's patented DehydraTECH(TM) technology enhances drug bioavailability, making it useful for a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions The company is currently exploring the potential benefits of DehydraTECH related to several molecules including, purified nicotine, CBD, antiviral drugs, human hormones, and PDE5 inhibitors Lexaria recently announced the completion of its diabetes animal study DIAB-A22-1 with at least three positive outcomes using DehydraTECH-CBD California-based InClin, Inc. has been awarded the contract for clinical research organization services for the expected upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1…

TuesdayMay 16, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off FDA IND Filing Process with Granted CRO Contract to California-Based InClin, Inc.

Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company’s upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1 InClin will manage the study in the form of clinical site evaluation and selection, project management, personnel, site training, and more Patient dosing is set to kick off as soon as possible once the expected FDA IND filing and review is completed, which Lexaria hopes will be done this summer HYPER-H23-1 will be Lexaria’s most ambitious study yet, and upon its completion, it will move the company closer to FDA approval of…

ThursdayMay 11, 2023 9:45 am

BizCann Expo: An Elite Business & Networking Event for All Things Cannabis

BizCann Expo, a must-attend event for anyone working in the cannabis space, will be held in the city of Medellín, Columbia, May 20-21, 2023, a beautiful location surrounded by the spectacular Andes mountains. Colombia’s location an1d promising regulatory environment make it a rich location for the cannabis industry, with Medellin and nearby regions guiding its growth. BizCann is the leading event in South and Latin America driving education, entrepreneurship, and innovation in all facets of the cannabis industry. Whether you’re a recognized canna-entrepreneur, or you are looking to join this exhilarating industry, BizCann Expo has all the resources you’ll need…

WednesdayMay 10, 2023 10:30 am

2023 Alternative Products Expo, Medellin, to Network and Expand Your Business in a Single Comprehensive Event

Professionals, retailers, distributors, and enthusiasts are invited to attend the one-of-a-kind Alternative Products Expo to be held in Medellin, Colombia, from May 20-21, 2023. It’s a uniquely all-inclusive event that brings together the multi-billion-dollar alternative products industry into one comprehensive setting. Every mainstream product has an alternative counterpart. The Alternative Products Expo is the one-stop destination to meet the prominent counterculture manufacturers and take advantage of the latest innovations and trends, show discounts, and network in the industry. By bringing the alternative community together, the expo seeks to provide industry professionals with a unique and immersive opportunity for business expansion…

MondayMay 08, 2023 11:15 am

The 2023 Alternative Products Expo – Everything Counterculture Under One Roof

ZJ Events is proud to announce the 2023 Alternative Products Expo, the ultimate gathering for smoke shop owners, independent retailers, buyers, and counterculture enthusiasts. This event looks to build on the success and momentum of previous events dating back to 2019, which have achieved massive success and offered incredible value and exposure to attendees. The Alternative Products Expo offers an avenue for anyone in the counterculture industry to connect with top manufacturers, explore the latest trends and innovations, and take advantage of exclusive show discounts in a fun and exciting atmosphere. Termed the largest vape, hemp, and counterculture expo, this…

MondayMay 08, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Four New Patents Added to the Company’s Growing Patent Portfolio

Lexaria has received notifications of four new patents either awarded or allowed After the awarding of these patents, Lexaria's total patent portfolio will have grown to 32 granted patents worldwide The new granted patent in Japan is under Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents The new granted Australian patent is under Patent Family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents The new allowed Canadian patent is under Patent Family #8: Compositions Infused with Nicotine Compounds and Methods of Use Thereof The new allowed US patent is under Patent Family #21: Compositions and…

WednesdayMay 03, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX), Featured in Recent Research Report by Zacks SCR

Zacks recently released a research report covering Lexaria Bioscience, a global innovator in drug delivery platforms The report discusses the company’s ongoing research and development (“R&D”) programs, forecasting penetration into global markets for hypertension, oral nicotine delivery, and antiviral product categories Lexaria is targeting conditions with significant market potential, including hypertension, diabetes, dementia, and seizures These programs position the company for entry into collaborative opportunities to support further growth and provide growth capital Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, featured in a recently released research report from Zacks Small-Cap Research (“SCR”) (https://cnw.fm/R891E). The report considers…

FridayApr 28, 2023 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Successful DIAB-A22-1 Diabetes Study Indicates Just One of Several Potential Applications for DehydraTECH(TM) Drug Delivery Platform Technology

Lexaria recently completed its diabetes animal model study, DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of diabetes The study showed at least three primary positive outcomes, including weight loss and improved triglyceride and cholesterol levels, with lower doses of DehydraTECH-CBD achieving the most optimum outcome The success of this study inches Lexaria closer to capitalizing on the potential of the diabetes drug market, estimated at $63.1 billion in 2021 It also points to the technology’s effectiveness, particularly following the success of the company’s most ambitious clinical study, HYPER-H21-4, demonstrating the…

MondayApr 17, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes the Licensed Use of its DehydraTECH(TM) Technology to Complement its Royalty Earnings and Realize Revenue in Advance of Royalties

Chris Bunka, Lexaria’s CEO, has reiterated the company’s commitment to creating value for its shareholders with the licensed use of its patented DehydraTECH(TM) technology Mr. Bunka has noted that Lexaria is already in discussions with interested parties in Europe and North America, a move that presents a critical fiscal opportunity for the company He has emphasized how profitable new licensing agreements could be for the company, presenting additional avenues for Lexaria to generate revenue and create value for its shareholders As the company continues to make a transition toward a more commercial focus in 2023, Bunka notes that licensing will…

MondayApr 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Revolutionizing Drug Delivery Potential for Active Pharmaceutical Ingredients Using Patented DehydraTECH(TM) Technology

DehydraTECH(TM)-enabled drugs and product formats improve the speed of onset, increase bioavailability, increase brain absorption, enhance drug potency, reduce drug administration costs, and mask unwanted tastes, shown effective with a growing number of medical applications Current DehydraTECH studies (animal and human) include hypertension, dementia, oral nicotine, epilepsy, and diabetes Most recently, Lexaria’s DehydraTECH-CBD studies for hypertension have produced positive results, and the company is seeking IND status with the FDA Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a disruptive drug delivery technology with multiple opportunities for success in cannabinoids, oral nicotine and other active…

News and publishing service for hemp related companies

Contact us: 512.354.7000

Category: Uncategorized